Anna Ehrlund1, Juan R Acosta1, Christel Björk1, Per Hedén2, Iyadh Douagi3, Peter Arner1, Jurga Laurencikiene1. 1. Lipid Laboratory, Department of Medicine Huddinge, Karolinska Institutet, Stockholm SE-14186, Sweden. 2. Akademikliniken, Storängsvägen 10, Stockholm SE-115 42, Sweden. 3. Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, Stockholm SE-14186, Sweden.
Abstract
Obesity affects gene expression and metabolism of white adipose tissue (WAT), which results in insulin resistance (IR) and type 2 diabetes. However, WAT is a heterogeneous organ containing many cell types that might respond differently to obesity-induced changes. We performed flow cytometry sorting and RNA expression profiling by microarray of major WAT cell types (adipocytes, CD45-/CD31-/CD34+ progenitors, CD45+/CD14+ monocytes/ macrophages, CD45+/CD14- leukocytes), which allowed us to identify genes enriched in specific cell fractions. Additionally, we included adipocytes and adipocyte progenitor cells obtained from lean and obese individuals. Taken together, we provide a detailed gene expression atlas of major human adipose tissue resident cell types for clinical/basic research and using this dataset provide lists of cell-type specific genes that are of interest for metabolic research.
Obesity affects gene expression and metabolism of white adipose tissue (WAT), which results in insulin resistance (IR) and type 2 diabetes. However, WAT is a heterogeneous organ containing many cell types that might respond differently to obesity-induced changes. We performed flow cytometry sorting and RNA expression profiling by microarray of major WAT cell types (adipocytes, CD45-/CD31-/CD34+ progenitors, CD45+/CD14+ monocytes/ macrophages, CD45+/CD14- leukocytes), which allowed us to identify genes enriched in specific cell fractions. Additionally, we included adipocytes and adipocyte progenitor cells obtained from lean and obese individuals. Taken together, we provide a detailed gene expression atlas of major human adipose tissue resident cell types for clinical/basic research and using this dataset provide lists of cell-type specific genes that are of interest for metabolic research.
Obesity and its comorbidities are major health problems in modern society. Expansion
of white adipose tissue (WAT) is often associated with fat cell hypertrophy (few,
but large cells), low-grade chronic inflammation, changes in WAT-resident immune
cell populations and altered secretion of proteins (adipokines) and lipids, all of
which are important for the development of insulin resistance (IR), type 2 diabetes,
hyperlipidemia and atherosclerosis[1-3].WAT is a heterogeneous organ composed of many cell types including adipocytes,
adipocyte progenitor cells, endothelial cells, fibroblasts and various types of
immune cells[4-6]. Less
than 50% of the cells are the tissue specific fat cells. Obesity has a complex
impact on WAT by affecting distinct cell populations differently. In obese WAT,
macrophages acquire a pro-inflammatory phenotype[7], the relative abundance of lymphocyte populations is
changed[8], and endothelial
cells are activated[9]. In addition,
WAT expansion causes changes in the progenitor cell population, and a change of
caloric intake can affect differentiation/recruitment of new fat cells[10,11].WAT metabolic alterations caused by obesity are also reflected in gene expression, a
measurement often used in clinical studies. mRNA profiling of WAT obtained from
lean/obese individuals or before/after weight reduction is commonplace, e.g. refs
12–15. However, such
an approach neither gives insights into the changes within specific cell types nor
enables prediction of intracellular gene regulatory networks as obesity-affected
genes might be differentially expressed in various WAT cell types. Only a few
studies have tried to address these questions comparing gene expression in paired
samples of SVF and adipocytes[16] or
analyzing expression in one particular cell fraction (magnetic-bead sorted
macrophages/monocytes)[17].
Systemic comparison of transcriptomes in WAT cell types is lacking, but is of great
interest for the field.The aims of the current study were to determine transcriptomic profiles of the major
cell types in human WAT and thus enable investigations of previously published
obesity-regulated genes[13], or
other WAT-genes of interest, in relevant WAT cell populations. We also aimed to
investigate how obesity affects gene expression and function of human adipocyte
progenitor cells. The adipocyte progenitors are highly relevant for WAT morphology
and metabolic phenotype as hyperplastic WAT (many, small fat cells) reflects
efficient recruitment/differentiation of adipocyte progenitors and is associated
with a favourable metabolic profile while hypertrophic WAT (few, large fat cells) is
closely linked to a pernicious metabolic profile and IR[18,19]. The
adipocytes have direct effects on whole body energy homeostasis by regulating lipid
turnover and secretion of adipokines like adiponectin and leptin.To address these questions in human WAT, we used flow cytometry sorting of the stroma
vascular fraction (SVF) of WAT, performed transcriptional profiling in four major
cell populations, and compared mRNA expression in adipocyte progenitor cells and
adipocytes from lean and obese individuals (Fig.
1). Here we provide a full transcriptomic dataset for major WAT cell
types as well as trancriptome of adipocyte progenitors and adipocytes obtained from
lean and obese individuals. Analysis of fraction-enriched genes is also provided as
an additional useful tool for the researchers in the field.
Figure 1
Outline of the project.
Methods
Human subjects and metabolic measurements
Subcutaneous (sc)WAT from 10 healthy obese and 10 non-obese healthy individuals
undergoing cosmetic plastic surgery was collected (Table 1). Obesity-regulated genes have been defined in WAT
from 56 non-obese/obesewomen[13]. All subjects were given written and oral information about
the study before they provided their written informed consent. The study was
approved by the regional committee on ethics at Karolinska Institutet.
Table 1
Patient characteristics and purity of sorted cell fractions*.
Patient ID
Patient
group
BMI
Age
Gender
Purity of
sorted populations (%)
Viability of SVF
(%)#
Progenitors
Macrophages
Leukocytes
142-2
lean
25
38
F
97.4
97.2
100
86.3
20
lean
24.7
45
F
97.9
97.5
99.5
81.7
26
lean
24.9
35
F
98.9
92.8
99
82.0
16
lean
25
39
F
95.6
94.9
99.1
86.5
124
lean
21.6
35
F
97.4
94.8
95.6
77.6
129
lean
21.9
40
F
95
94
93
75.2
28
lean
23.9
47
F
98.6
94.4
90.7
81.5
30
lean
23.4
37
F
97.1
100
98.3
73.7
31
lean
20.3
32
F
95
93.5
99
85.0
27
lean
20.8
30
F
100
93.7
97.2
84.5
98
obese
29.8
27
F
94.1
96.1
97.3
65.1
116
obese
30.1
27
F
96.7
95.7
98.8
76.7
109
obese
30.5
31
F
97.8
96.4
96.2
67.5
117
obese
32.2
18
F
97.1
97.1
93.7
83.6
100
obese
30.6
29
F
98.2
94.7
98.4
71.8
57
obese
32.2
31
M
95.3
92.5
80.8
78.0
29
obese
32.4
52
F
96.7
93
97.1
73.5
144
obese
37
42
M
95.2
93.7
99.2
68.2
74
obese
31.2
45
F
94
96.5
97.2
71.4
*Samples labeled in bold were used for RNA expression profiling.
Flow cytometry
scWAT SVF was isolated and cryopreserved, then stained and analyzed/collected by
FACS analysis as described[20].
Mature adipocytes were prepared in parallel of SVF preparation as
described[21]. The
antibodies used are specified in Table 2.
Progenitor cells (CD45−/CD34+/CD31−), endothelial cells
(CD45−/CD34+/CD31+), monocytes/macrophages (CD45+/CD14+) and leukocytes
(CD45+/CD14−) were collected for RNA purification. In addition, the
occurrence of T-cell population (CD45+/CD3+/CD14−) was recorded.
Table 2
Antibodies used for FACS sorting.
Specificity
Clone
Color
Company
anti-CD45
T29/33
Pacific Blue
DakoCytomation, Glostrup, Denmark
anti-CD14
M5E2
PE
BD biosciences, San Jose, CA, USA
anti-CD34
8G12
APC
BD biosciences, San Jose, CA, USA
anti-CD3
SK7
PerCP-Cy5.5
BD biosciences, San Jose, CA, USA
anti-CD31
WM59
FITC
BD biosciences, San Jose, CA, USA
RNA extraction
RNA from FACS-sorted cell fractions and SVF were extracted with RNeasy Micro Kit
(Qiagen, Hilden, Germany) and from adipocytes with RNeasy Lipid tissue kit
(Qiagen) in accordance with the manufacturer’s recommendations.
Microarray analysis
RNA expression was analyzed on Affymetrix GeneChip Human Transcriptome Array 2.0
(Affymetrix Inc., Santa Clara, CA) in accordance with the manufacturer’s
instructions. Arrays were normalized (RMA, transcript cluster level) in the
Expression Console (Affymetrix, Thermo Scientific).
Statistical analysis of microarray data
After RMA normalization in Affymetrix Expression console software all further
analysis of microarray data was carried out in R statistical software (http://CRAN.R-project.org/).
Quality control
After RMA normalization, the array quality was assessed using the
ArrayQualityMetrics package in R[22].
Enrichment in adipocyte, adipocyte progenitor, macrophage and leukocyte
fractions
We excluded array control transcripts before further analysis (by selecting
only transcripts with affymetrix category ‘main’) from this
step onward. Our data set contains adipocyte, adipocyte progenitor,
macrophage and leukocyte microarrays from RNA from 6 non-obese female
subjects. To identify genes enriched in one of the fractions versus all
others we used the Bioconductor R-package LIMMA[23]. We made paired, pairwise comparisons of
all fractions and selected probes for each fraction that had significantly
(Benjamini-Hochberg corrected P-value<0.05) higher
expression levels in that fraction compared to all others. We also
calculated moderated F-statistics for all genes and filtered out any genes
that were not significant (Benjamini-Hochberg adjusted
P-value<0.05) according to that analysis. The
R-code for this analysis can be found in Data Citation 1.
Differential expression in progenitors and adipocytes
Differential gene expression in progenitors and adipocytes from non-obese and
obesepatients was also determined using LIMMA[23]. Array probes without gene symbol annotation
were filtered out before LIMMA analysis.
Data Records
All microarray data are accessible on GEO (GSE80654) (Data Citation 2) and analysis files are provided as supplemental tables
(Data Citation 3, Data Citation 4, Data Citation
5 and Data Citation 6).
Description of files
File 1: Microarray data are decribed in Data
Citation 2.File 2: Tables of fraction-specific genes (Data
Citation 3). RNA from non-obese paired adipocyte, leukocyte,
macrophage/monocyte and adipocyte progenitor fractions (from six non-obesewomen) were analyzed and cell-fraction enriched genes were defined as described
under methods and R-code (Data Citation 1
and Data Citation 3).File 3: Pairwise comparison of adipose cell fractions: RNA from non-obese paired
adipocyte, leukocyte, macrophage/monocyte and adipocyte progenitor were compared
to each other and differentially expressed genes defined as described in methods
and R-code (Data Citation 4).File 4: Table with obesity-regulated genes in progenitors. Effect of obesity on
RNA expression in adipocyte progenitor cells was analyzed using samples from 10
non-obesewomen, 7 obesewomen and 2 obesemen (Data Citation 5).File 5: Table with obesity-regulated genes in adipocytes. Effect of obesity on
RNA expression in purified mature adipocytes was analyzed using samples from 8
lean women, 5 obesewomen and 1 obeseman (Data
Citation 6).
Technical Validation
Quality control of FACS sorting
Purity of each FACS-sorted fraction was evaluated by post-sort analysis. Mean
purity of adipocyte progenitor cells was 97.7±1.68%; endothelial cells:
77.5±11.9%; monocytes/macrophages: 95.1±2.9%; leukocytes:
98.8±0.87%. Individual values of purity for each sample are shown in
Table 1. Viability of cells was
generally between 85% and 70% and was determined by 7-aminoactinomycin D
(7-AAD)[20] and by
distribution on SSC/FSC scatters where alive and dead cells constituted distinct
populations. Samples with lower viability than 65% were not used for the
analysis. SVF viability for each sample is indicated in Table 1. Functional validation of FACS sorting quality was
performed by inducing adipogenesis in vitro in all sorted
fractions. Only progenitor cells and total SVF had capacity to differentiate.
Purity of adipocyte preparation was examined in an earlier study and was found
to be 99%[24]. A sorting scheme,
flow cytometry plots, gating strategy and cell fraction frequencies are shown in
Fig. 2. Differentiation ability of
progenitor, monocyte/macrophage and leukocyte fractions are shown in Fig. 3.
Figure 2
Flow cytometry analysis of human subcutaneous adipose tissue stroma vascular
fraction (SVF).
(a) Representative FACS profiles and gating strategy with marked
populations of cells used for analysis. (b) Relative frequency of
cell populations in lean and obese SVF (*P<0.05, lean
n=10, obese n=9). Non-obese and obese
groups were compared by multiple T-test. Means and standard
deviations are shown.
Figure 3
Differentiation of FACS-sorted fractions.
(a) Pictures of the cells one day after FACS-sorting/plating, before
the induction of adipogenic differentiation. (b) Pictures of the
cells at day 13 of differentiation. DNA dye Hoechst was used to visualize nuclei
representing total amount of cells and neutral lipid dye Bodipy 493/503 was used
to visualize lipid droplets.
Quality control of RNA integrity
To determine RNA quality, Agilent 2100 Bioanalyzer (Agilent Technologies Inc.,
Santa Clara, CA) was used. The integrity of RNA was calculated using RIN (RNA
integrity number) algorithm, where higher numbers indicate higher quality, a
maximum value being 10. Mean RIN value of the samples was 7.9 and lowest
acceptable RIN in this study was 6.6. In adipocyte fraction, RIN values
reflected well the amount of viable cells in the preparation.
Quality control of microarray profiling
RMA normalized data was quality controlled using the ArrayQualityMetrics
package[22] in R (Fig. 4c–g). Principal component
analysis performed in R showed that samples grouped on cell fraction. The two
immune cell fractions, leukocytes and macrophages/monocytes were separated by
PC1/PC3 (Fig. 4b) and formed distinct
clusters in array distance distribution pseudo-heat map (Fig. 4d). The array signal intensity indicated that two
adipocyte samples (JL41_M_4 (non-obese) and JL51_M_17 (obese)) as outliers
(Fig. 4c,f) but as neither MA-plots nor
array distance analysis identified these samples as outliers (Fig. 4e,g), nor did the PCA analysis show
these samples to be distant from others. Thus, we kept them in our downstream
analyses. Quality of microarray profiling was also verified by RT-qPCR examining
expression of known cell-type-enriched genes in all four major SVF fractions
(Fig. 5a) and obesity-regulation of
genes in progenitor cell fraction (Fig. 5b)
(primers listed in Table 3).
Figure 4
Quality control of microarray data.
(a) Color coding of samples throughout this figure. (b)
Principal component analysis plot with PC1 versus PC2 and PC1 versus PC3 showing
separation of the sorted fractions. (c) Box plot of array distance
distributions after RMA normalization. (d) Heatmap of distance
between arrays. Color scale covers the range of distances encountered between
the arrays. (e,f,g) Outlier detection in
array QualityMetrics based on the specified parameters. Only two possible
outliers were detected, one adipocyte non-obese and one adipocyte obese sample
(* in f). As this was based on signal intensity distribution alone
and none of the other two outlier detection method called these (or other)
samples, we decided to keep them in the analysis.
Figure 5
Technical validation of microarray by RT-qPCR.
(a) Relative expression of selected known fraction-specific genes in
four cell fractions from lean individuals (n=3–5).
Groups are compared by multiple T-test and all fraction
specific genes are significantly higher in the expected fraction (adjusted
P<0.05). Means and standard deviations are shown.
(b) Relative expression of selected genes in lean
(n=8) and obese (n=7) women. Inclusion of
2 obese men in the obese group (original microarray cohort) does not affect
significance for any of the tested genes. Groups are compared by
T-test (**P<0.01). Mean and
standard deviations are shown. n.d.—not detected.
Table 3
Sybrgreen primer sequences.
Gene name
Forward primer
Reverse primer
CNTN3
GAGAACTGTCATATGCTTGG
CTTAGATATGTAGAGGTGCCC
ENPEP
CTACACTCTTGAGCAATACC
ACCTTGACAAAAGAGTAACG
HAS2
GATGCATTGTGAGAGGTTTC
CCGTTTGGATAAACTGGTAG
PLIN1
CAGAATGAAGACCTAAATGACC
ATGCATCGTACCATCTACTG
18S
TGACTCAACACGGGAAACC
TCGCTCCACCAACTAAGAAC
Usage Notes
Genes enriched in specific WAT cell fractions
In clinical studies, it is often impossible for ethical reasons to obtain enough
material to study the effect of different conditions/treatments in the
individual cell types of WAT. However, when moving from gene associations to
functional studies, the cell type that a gene is primarily expressed in is a
crucial clue for designing experiments. Our data set provides a way to assess
this, and we provide lists of genes enriched in each of the four cell types we
sorted (Data Citation 3). Besides
fraction-enriched gene lists, tables include mean expression of the gene in a
fraction where it is enriched, log fold change (logFC) compared to each of other
fractions and adjusted P values (adj.P.Val). Minimal logFC and
maximal adj.P.Val against other fractions are included as separate columns to
enable easy sorting of the data. A table where 100 highest-ranked genes from
each fraction (based on highest logFC_min and lowest adj.P.val_max) is also
provided (Data Citation 3). We also
provide pairwise comparisons between all fractions so that researchers can
quickly check the magnitude of the differential expression for a specific gene
(Data Citation 4). The results are
summarized in Venn diagrams (Fig.
6a–d).
Figure 6
Venn Diagrams of differentially expressed genes compared to other cell
fractions.
Genes differentially expressed in adipocyte progenitors (a),
adipocytes (b), macrophages/monocytes (c), leukocytes
(d). Amount of genes enriched in the indicated fraction
compared to the other three is shown in the middle of the graphs.
Our enrichment analysis is well in line with previously reported data. For
example the well known ‘markers’ Adiponectin (ADIPOQ), Leptin
(LEP) and Perilipin-1 (PLIN1) were among the top enriched adipocyte genes, CD3G
and CD69 were enriched in leukocytes, MMP2 and COL1A2-in adipocyte progenitors.
In the monocyte/macrophage fraction we found 23 out of 24 earlier reported WAT
macrophage-specific genes[17]
among the most enriched. Only HLA-DRA from the previous study was not defined as
macrophage/monocyte-enriched, which goes well with it’s reported
expression in all types of antigen-presenting cells, such as B-lympocytes,
dendritic cells and others[25].
There are also lesser known fraction-enriched genes, of particular interest may
be the non-coding genes, that to date have not been well characterized.
Splicing and non-coding transcripts
The Human transcriptome 2.0 arrays contain exon level information and can be used
to analyze splicing using e.g., the affymetrix software ‘Transcriptome
analysis console’ that is available for free download on
Affymetrix/ThermoFisher Scientific’s webpage https://www.thermofisher.com/se/en/home/life-science/microarray-analysis/microarray-data-analysis/genechip-array-annotation-files.html.
This analysis can be useful for determining e.g., differential splicing between
cell types, or the expression of a specific splice variant in a cell type.Furthermore, the HTA2.0 array contains probes for many non-protein coding
transcripts, which many other older arrays do not. Thus, this data set can be of
specific importance for researchers in e.g., the lncRNA field. Annotation to all
included probes can be obtained from Affymetrix/Thermo Scientific’s
webpage as indicated above.
Effects of obesity on scWAT adipocyte progenitor cells
To investigate how gene expression in human adipose progenitors is affected by
obesity, we performed microarray analysis on this cell fraction in 10 non-obese
and 9 obese individuals. We were primarily interested in annotated genes so we
filtered out all probesets without an associated gene symbol before the start of
the analysis. When global gene expression in non-obese and obese WAT progenitors
was compared, all multiple hypothesis corrected P-values were
>0.05, probably due to small cohort size and the still large amount of
transcripts tested. However, even if false discovery rate is rather high in this
data set alone, it may still be used for hypothesis generation, especially when
combined with other data and perhaps also with cut-offs on e.g., gene expression
fold change. To see whether such an approach had any merit we selected genes
that had an unadjusted P-value <0.05 and ≥50%
up-/downregulation. This gave 35 genes (Data
Citation 5), including DKK1[26], CD36[27] and BMP2[28], known to be involved in regulation of adipogenesis and
progenitor proliferation. To add more value to biological significance of our
findings, we have selected genes that are regulated by obesity in progenitors
and highly enriched in this fraction (15 out of 34 genes). We assumed that in
intact adipose tissue, most of the expression detected from these genes is
coming from progenitor cells. Therefore, we investigated obesity-regulation of
these 15 genes in the earlier published cohort reporting obesity-regulated genes
in intact WAT[13]. Out of 15
genes, 13 were found in this dataset and 9 of them were regulated by obesity
with 5% FDR. This suggests that even this small dataset of obesity
regulated-progenitor genes can be used for hypothesis generation before deeper
functional studies when combined with other data sets or in larger
transcriptomic studies.
Additional information
How to cite this article: Ehrlund, A. et al. The
cell-type specific transcriptome in human adipose tissue and influence of obesity on
adipocyte progenitors. Sci. Data 4:170164 doi:
10.1038/sdata.2017.164 (2017).Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Authors: N Viguerie; H Vidal; P Arner; C Holst; C Verdich; S Avizou; A Astrup; W H M Saris; I A Macdonald; E Klimcakova; K Clément; A Martinez; J Hoffstedt; T I A Sørensen; D Langin Journal: Diabetologia Date: 2004-12-29 Impact factor: 10.122
Authors: Juan R Acosta; Iyadh Douagi; Daniel P Andersson; Jesper Bäckdahl; Mikael Rydén; Peter Arner; Jurga Laurencikiene Journal: Diabetologia Date: 2015-11-25 Impact factor: 10.122
Authors: Chuan Li; Antoine Menoret; Cullen Farragher; Zhengqing Ouyang; Christopher Bonin; Paul Holvoet; Anthony T Vella; Beiyan Zhou Journal: JCI Insight Date: 2019-04-16
Authors: Sindre Lee; Frode Norheim; Torgrim M Langleite; Hanne L Gulseth; Kåre I Birkeland; Christian A Drevon Journal: Diabetologia Date: 2019-04-22 Impact factor: 10.122